BMRN Q3 2023 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$581M+15.0% YoY

Gross Profit

$453M78.0% margin

Operating Income

$31M5.3% margin

Net Income

$40M6.9% margin

EPS (Diluted)

$0.21

QoQ Revenue Growth

-2.3%

Cash Flow

Operating Cash Flow

$136M

Free Cash Flow

$112M

Stock-Based Comp.

$48M

Balance Sheet

Total Assets

$6.8B

Total Liabilities

$1.9B

Stockholders' Equity

$4.9B

Cash & Equivalents

$785M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$581M	$505M	+15.0%
Gross Profit	$453M	$389M	+16.5%
Operating Income	$31M	-$2M	+1362.9%
Net Income	$40M	-$7M	+707.0%

Revenue Segments

Product

$568M58%

Enzyme Product

$402M41%

Royalty And Other

$13M1%